Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis

NCT03239860 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
220
Enrollment
INDUSTRY
Sponsor class

Stopped Based on R\&D strategic reasons, our co-development Partner financing the study disengaged from the development of GNbAC1.

Conditions

Interventions

Sponsor

GeNeuro SA

Collaborators